Comparison of heart-type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myocardial infarction

Kagawa, Y.; Toyofuku, Mamoru; Masaoka, Yoshiko; Muraoka, Yuji; Okimoto, Tomokazu; Otsuka, Masaya; Tamekiyo, Hiromichi; Mito, Shinji; Kawase, Tomoharu; Yamane, Kunio; Senoo, Atsuhiro; Amioka, Michitaka; Shiode, Nobuo; Hayashi, Yasuhiko

doi:10.1016/j.ijcard.2011.10.080

Cited by 22 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, eight studies (Table 1) were included for quantitative analysis. [15][16][17][18][19][20][21][22] Overall, 3395 patients were included in the final analysis. Among these, 716 patients (21.1%) were eventually diagnosed with AMI according to the Universal Definition.…”

Section: Resultsmentioning

confidence: 99%

“…Patients with ST elevation MI (STEMI) were included in four studies, 16,19,20,22 while one study exclusively enrolled patients at low cardiovascular risk. 17 The trials were set in the Emergency Department in seven studies [15][16][17][19][20][21][22] and the coronary care unit in one. 18 Four studies had a prospective design, 15,[20][21][22] while the rest performed retrospective analyses of frozen plasma samples.…”

Section: Resultsmentioning

confidence: 99%

“…17 The trials were set in the Emergency Department in seven studies [15][16][17][19][20][21][22] and the coronary care unit in one. 18 Four studies had a prospective design, 15,[20][21][22] while the rest performed retrospective analyses of frozen plasma samples. Three studies used hsTnI, 19,20,22 four used hsTnT 15,16,21 and one assayed both.…”

Section: Resultsmentioning

confidence: 99%

“…In comparison to hsTn, however, the diagnostic performance of HT FABP appears consistently poor irrespective of the time delay between symptom onset and presentation. Collinson et al, 17 Reiter et al 21 and Ruff et al 22 all demonstrated poor performance of HT FABP against hsTn even in early presenters (<3-6 h), while Eggers et al, 18 Kagawa et al 20 and Ilva et al 19 found the diagnostic performance of HT FABP against hsTn to be equally poor between early and late presenters. The interaction between the timing of sampling and combined HT FABP/hsTn appears more complex.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis

Liou

2014

Ann Clin Biochem

View full text Add to dashboard Cite

Introduction: Heart-type fatty acid binding protein (HT FABP) is an emerging biomarker of ischaemic myocardial necrosis. While previous studies have demonstrated its additive value when compared to contemporary troponin assays in the diagnosis of acute myocardial infarction (AMI), its utility in the era of high-sensitivity troponin (hsTn) assays remains undetermined. Methodology: A systematic review and meta-analysis of relevant studies was performed comparing the diagnostic performance of HT FABP both alone and in conjunction with hsTn in the early diagnosis and exclusion of AMI. Results: A systematic literature search yielded eight eligible studies including 3395 patients. Of these, 716 patients (21.1%) were eventually diagnosed with AMI. The pooled sensitivity and specificity for hsTn on admission was 82.5% (95% confidence interval [CI]: 79.8-85.0%) and 89.7% (95% CI: 88.7-90.6%), respectively, while the area under the curve (AUC) for the summary receiver operating characteristics (ROC) curve is 0.92 (SE 0.02). While the pooled specificity (84.6%, 95% CI: 83.2-85.9%) of admission HT FABP is similar to hsTn for the early diagnosis of AMI (P ¼ 0.07), its pooled sensitivity (63.5%, 95% CI: 59.9-67.1%, P < 0.001) is significantly worse. Accordingly, the AUC of the summary ROC curve for HT FABP (0.79, SE 0.03) is inferior to hsTn (P < 0.0001). The addition of HT FABP to hsTn resulted in no improvement in the sensitivity (P ¼ 0.058) and worsened the specificity (P ¼ 0.001) in the early diagnosis of AMI compared to hsTn alone. Conclusion: HT FABP does not appear to improve the diagnostic accuracy of hsTn, and consequently its routine use currently cannot not be recommended.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis

Liou

2014

Ann Clin Biochem

View full text Add to dashboard Cite

show abstract

“…hFABP can be of added clinical value, especially in a multimarker approach (3,4,24,26,31), but contradictory evidence exists (1,19,30). This may stem from difficulties in estimating the time from onset of ischemia to presentation, as well as variations in onset of spontaneous reperfusion and presence of collateral flow.…”

Section: H1106 Hfabp For Acute Myocardial Infarct Size and No-reflowmentioning

confidence: 99%

Serial measurement of hFABP and high-sensitivity troponin I post-PCI in STEMI: how fast and accurate can myocardial infarct size and no-reflow be predicted?

Uitterdijk

Sneep

Duin

et al. 2013

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

The objective of this study was to compare heart-specific fatty acid binding protein (hFABP) and high-sensitivity troponin I (hsTnI) via serial measurements to identify early time points to accurately quantify infarct size and no-reflow in a preclinical swine model of ST-elevated myocardial infarction (STEMI). Myocardial necrosis, usually confirmed by hsTnI or TnT, takes several hours of ischemia before plasma levels rise in the absence of reperfusion. We evaluated the fast marker hFABP compared with hsTnI to estimate infarct size and no-reflow upon reperfused (2 h occlusion) and nonreperfused (8 h occlusion) STEMI in swine. In STEMI (n = 4) and STEMI + reperfusion (n = 8) induced in swine, serial blood samples were taken for hFABP and hsTnI and compared with triphenyl tetrazolium chloride and thioflavin-S staining for infarct size and no-reflow at the time of euthanasia. hFABP increased faster than hsTnI upon occlusion (82 ± 29 vs. 180 ± 73 min, P < 0.05) and increased immediately upon reperfusion while hsTnI release was delayed 16 ± 3 min (P < 0.05). Peak hFABP and hsTnI reperfusion values were reached at 30 ± 5 and 139 ± 21 min, respectively (P < 0.05). Infarct size (containing 84 ± 0.6% no-reflow) correlated well with area under the curve for hFABP (r(2) = 0.92) but less for hsTnI (r(2) = 0.53). At 50 and 60 min reperfusion, hFABP correlated best with infarct size (r(2) = 0.94 and 0.93) and no-reflow (r(2) = 0.96 and 0.94) and showed high sensitivity for myocardial necrosis (2.3 ± 0.6 and 0.4 ± 0.6 g). hFABP rises faster and correlates better with infarct size and no-reflow than hsTnI in STEMI + reperfusion when measured early after reperfusion. The highest sensitivity detecting myocardial necrosis, 0.4 ± 0.6 g at 60 min postreperfusion, provides an accurate and early measurement of infarct size and no-reflow.

show abstract

Evaluation of heart fatty acid‐binding protein as a biomarker for canine leishmaniosis

et al. 2023

View full text Add to dashboard Cite

Background: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid-binding protein (HFABP) is a biomarker of myocardial damage. Methods: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty-one dogs diagnosed with CanL and 10 healthy dogs were included. Results: HFABPc was not statistically different (p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin (r = −0.519; p = 0.03) and haematocrit (HCT) (r = −0.538; p = 0.02) was observed. No other significant correlation (p > 0.05) was observed with any other variable. Limitations: Many statistical tests were performed, and therefore, type I error cannot be ruled out. Conclusion: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease.

show abstract

Comparison of heart-type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myocardial infarction

Cited by 22 publications

References 14 publications

Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis

Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis

Serial measurement of hFABP and high-sensitivity troponin I post-PCI in STEMI: how fast and accurate can myocardial infarct size and no-reflow be predicted?

Evaluation of heart fatty acid‐binding protein as a biomarker for canine leishmaniosis

Contact Info

Product

Resources

About